Search research articles
Contact Us
Filters
Showing results (51-60 of 57) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 57 results.
The Lancet Regional Health. Southeast Asia
|
August 1, 2025
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
The Lancet Regional Health. Southeast Asia
|
March 11, 2026
Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
Subhash Thuluva, Ramesh V Matur, Subbareddy Gunneri, et al.
Asiaintervention
|
March 20, 2023
Clinical use of optical coherence tomography during percutaneous coronary intervention and coronary procedures in Southeast Asia: a survey-based expert consensus summary
Adrian F Low, Nattawut Wongpraparut, Narathip Chunhamaneewat, et al.
Scientific Reports
|
December 6, 2025
Real-world study to compare functional SYNTAX score versus anatomical SYNTAX score in influencing the treatment strategy for multivessel disease patients
Nattawut Wongpraparut, Sivakumar Rathnavel, Mann Chandavimol, et al.
Indian Heart Journal
|
May 27, 2023
Effectiveness and safety of optical coherence tomography-guided PCI in Indian patients with complex lesions: A multicenter, prospective registry
Praveen Chandra, Selvamani Sethuraman, Sanjeeb Roy, et al.
Vaccine
|
November 3, 2022
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Vaccines
|
June 25, 2026
Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14<sup>®</sup>) Administered at 6-10-14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
Subhash Thuluva, Subbareddy Gunneri, Siddalingaiah Ningaiah, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 57) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 57 results.
The Lancet Regional Health. Southeast Asia
|
August 1, 2025
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
The Lancet Regional Health. Southeast Asia
|
March 11, 2026
Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
Subhash Thuluva, Ramesh V Matur, Subbareddy Gunneri, et al.
Asiaintervention
|
March 20, 2023
Clinical use of optical coherence tomography during percutaneous coronary intervention and coronary procedures in Southeast Asia: a survey-based expert consensus summary
Adrian F Low, Nattawut Wongpraparut, Narathip Chunhamaneewat, et al.
Scientific Reports
|
December 6, 2025
Real-world study to compare functional SYNTAX score versus anatomical SYNTAX score in influencing the treatment strategy for multivessel disease patients
Nattawut Wongpraparut, Sivakumar Rathnavel, Mann Chandavimol, et al.
Indian Heart Journal
|
May 27, 2023
Effectiveness and safety of optical coherence tomography-guided PCI in Indian patients with complex lesions: A multicenter, prospective registry
Praveen Chandra, Selvamani Sethuraman, Sanjeeb Roy, et al.
Vaccine
|
November 3, 2022
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Vaccines
|
June 25, 2026
Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14<sup>®</sup>) Administered at 6-10-14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
Subhash Thuluva, Subbareddy Gunneri, Siddalingaiah Ningaiah, et al.
Page
of 6